Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | GGT1 | P19440 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418282 | 0.92 | NOD1 (0.54) | NOD1GPR84FFAR1FOLH1MAPT | |
| SCHEMBL9577616 | 0.92 | NOD1 (0.54) | NOD1GPR84FFAR1FOLH1MAPT | |
| SCHEMBL146216 | 0.92 | NOD1 (0.56) | NOD1CA2MAPK1ACHEBACE1 | |
| SCHEMBL8415545 | 0.92 | NOD1 (0.56) | NOD1CA2MAPK1ACHEBACE1 | |
| SCHEMBL3416074 | 0.90 | NOD1 (0.58) | NOD1CA2MAPK1GPR84FFAR1 | |
| SCHEMBL9831562 | 0.90 | NOD1 (0.58) | NOD1CA2MAPK1GPR84FFAR1 | |
| SCHEMBL28794255 | 0.88 | NOD1 (0.61) | NOD1GPR84FFAR1FOLH1MAPT | |
| SCHEMBL30957009 | 0.88 | NOD1 (0.61) | NOD1GPR84FFAR1FOLH1MAPT | |
| SCHEMBL8413851 | 0.87 | CHRM1 (0.46) | NOD1CA2MAPK1GGT1CTSK | |
| SCHEMBL148236 | 0.87 | CHRM1 (0.46) | NOD1CA2MAPK1GGT1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461332-A2 | PRODUCTION OF CHIRALLY PURE ALPHA-AMINO ACIDS AND N-SULFONYL ALPHA-AMINO ACIDS | Wyeth (US) | 2004-09-29 | — | — | EP | claimed |
| US-6657070-B2 | Such as N-((5-chloro-2-thienyl)sulfonyl)-3-ethylnorvaline and 5-chloro-N-((S)-2-ethyl-1-formylbutyl)thiophene-2-sulfonamide via reacting aldehyde, cyanide salt, and alpha-methylbenzylamine | WYETH | 2003-12-02 | — | — | US | claimed |
| WO-2003050062-A2 | PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS | WYETH (US) | 2003-06-19 | — | — | WO | claimed |
| US-20030013892-A1 | Production of chirally pure alpha-amino acids and N-sulfonyl alpha-amino acids | WYETH | 2003-01-16 | — | — | US | claimed |
| EP-1461332-A2 | PRODUCTION OF CHIRALLY PURE ALPHA-AMINO ACIDS AND N-SULFONYL ALPHA-AMINO ACIDS | Wyeth (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6657070-B2 | Such as N-((5-chloro-2-thienyl)sulfonyl)-3-ethylnorvaline and 5-chloro-N-((S)-2-ethyl-1-formylbutyl)thiophene-2-sulfonamide via reacting aldehyde, cyanide salt, and alpha-methylbenzylamine | WYETH | 2003-12-02 | — | — | US | disclosed |
| WO-2003050062-A2 | PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS | WYETH (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030013892-A1 | Production of chirally pure alpha-amino acids and N-sulfonyl alpha-amino acids | WYETH | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013892-A1 | Production of chirally pure alpha-amino acids and N-sulfonyl alpha-amino acids | DNPEP, EDNRB, PNMT | NOD1 954/4885CA2 513/4885MAPK1 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.